Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5)

@inproceedings{Reddy2014DiscoveryO8,
  title={Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent
Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase
5 (ARK5)},
  author={M. Venkat Ramana Reddy and Balireddy Akula and Stephen C. Cosenza and Saikrishna Athuluridivakar and Muralidhar Reddy Mallireddigari and Venkat R. Pallela and Vinay K. Billa and Deepthi Subbaiah and E. Vijaya Bharathi and Rodrigo Vasquez-Del Carpio and A. S. Padgaonkar and Stacey J. Baker and E. P. Reddy},
  booktitle={Journal of medicinal chemistry},
  year={2014}
}
The success of imatinib, a BCR-ABL inhibitor for the treatment of chronic myelogenous leukemia, has created a great impetus for the development of additional kinase inhibitors as therapeutic agents. However, the complexity of cancer has led to recent interest in polypharmacological approaches for developing multikinase inhibitors with low toxicity profiles. With this goal in mind, we analyzed more than 150 novel cyano pyridopyrimidine compounds and identified structure-activity relationship… CONTINUE READING
BETA
1
Twitter Mention

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 67 REFERENCES

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2011

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2010

Similar Papers

Loading similar papers…